Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 8;4(23):5966-5975.
doi: 10.1182/bloodadvances.2020003170.

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A Wood  1 , Donna S Neuberg  2 , J Colton Thompson  3 , Martin S Tallman  4 , Mikkael A Sekeres  5 , Laurie H Sehn  6   7 , Kenneth C Anderson  8 , Aaron D Goldberg  4 , Nathan A Pennell  9 , Charlotte M Niemeyer  10 , Emily Tucker  3 , Kathleen Hewitt  3 , Robert M Plovnick  3 , Lisa K Hicks  11
Affiliations

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

William A Wood et al. Blood Adv. .

Abstract

Coronavirus disease 2019 (COVID-19) is an illness resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019. Patients with cancer, and especially those with hematologic malignancies, may be at especially high risk of adverse outcomes, including mortality resulting from COVID-19 infection. The ASH Research Collaborative COVID-19 Registry for Hematology was developed to study features and outcomes of COVID-19 infection in patients with underlying blood disorders, such as hematologic malignancies. At the time of this report, data from 250 patients with blood cancers from 74 sites around the world had been entered into the registry. The most commonly represented malignancies were acute leukemia (33%), non-Hodgkin lymphoma (27%), and myeloma or amyloidosis (16%). Patients presented with a myriad of symptoms, most frequently fever (73%), cough (67%), dyspnea (50%), and fatigue (40%). Use of COVID-19-directed therapies, such as hydroxychloroquine (n = 76) or azithromycin (n = 59), was common. Overall mortality was 28%. Patients with a physician-estimated prognosis from the underlying hematologic malignancy of <12 months at the time of COVID-19 diagnosis and those with relapsed/refractory disease experienced a higher proportion of moderate/severe COVID-19 disease and death. In some instances, death occurred after a decision was made to forgo intensive care unit admission in favor of a palliative approach. Taken together, these data support the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection. Batch submissions from sites with high incidence of COVID-19 infection are planned to support future analyses.

PubMed Disclaimer

Conflict of interest statement

Conflict--interst disclosure: D.S.N. received research support from Pharmacyclics; and holds stock in Madrigal. W.A.W. received research support from Pfizer; provided consulting for Teladoc; was an advisor for Koneksa Health and Elektra Labs; and received honoraria from the ASH Research Collaborative. L.K.H. received research support from Gilead. N.A.P. provided consulting for AstraZeneca, BMS, Merck, Genentech, Amgen, Eli Lilly, and G1 therapeutics. M.S.T. received research support from AbbVie, Cellerant, Orsenix, ADC Therapeutics, Biosight, Glycomimetics, Rafael Pharmaceuticals, and Amgen; served on advisory boards for AbbVie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight, and Novartis; and received royalties from UpToDate. C.M.N. provided consulting for Celgene and Novartis. A.D.G. served on advisory boards for AbbVie, Aptose, Celgene, Daiichi Sankyo, and Genentech; received research support from AbbVie, ADC Therapeutics, Aprea, Aptose, AROG, Celularity, Daiici Sankyo, and Pfizer; and received honoraria from Dava Oncology. L.H.S. received consulting or honoraria from Roche/Genentech, AbbVie, Amgen, Apobiologix, AstraZeneca, Acerta, Celgene, Gilead, Janssen, Kite Karyopharm, Lundbeck, Merck, Morphosys, Seattle Genetics, Teva, Takeda, TG Therapeutics, and Verastem. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Geographic distribution of cases reported to the ASH Research Collaborative COVID-19 Registry for Hematology (n = 248).
Figure 2.
Figure 2.
COVID-19 severity and mortality among patients with hematologic malignancies (n = 242). Patients for whom severity was not known were excluded.
Figure 3.
Figure 3.
COVID-19 severity, mortality, and decision to forgo ICU among patients with hematologic malignancies by patient age (n = 222). Patients for whom severity outcomes were not known were excluded.
Figure 4.
Figure 4.
COVID-19 severity, mortality, and decision to forgo ICU among patients with hematologic malignancies by estimated pre–COVID-19 prognosis (n = 183). Patients were included only if estimated prognosis was provided.
See this image and copyright information in PMC

References

    1. World Health Organization WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re.... Accessed 23 September 2020.
    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782-793. - PubMed
    1. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020;21(4):e181. - PMC - PubMed
    1. Fontana L, Strasfeld L. Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient. Infect Dis Clin North Am. 2019;33(2):523-544. - PMC - PubMed
    1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040. - PMC - PubMed

MeSH terms